Skip to main content Back to Top
Advertisement

10/11/2021

Flumazenil Injection

Products Affected - Description

    • Flumazenil injection, Baxter, 0.1 mg/mL, 5 mL vial, 10 count, NDC 36000-0148-10
    • Flumazenil injection, Fresenius Kabi, 0.1 mg/mL, 5 mL vial, 10 count, NDC 63323-0424-05
    • Flumazenil injection, Hikma, 0.1 mg/mL, 10 mL vial, 10 count, NDC 00143-9783-10
    • Flumazenil injection, Hikma, 0.1 mg/mL, 5 mL vial, 10 count, NDC 00143-9784-10

Reason for the Shortage

    • Baxter has flumazenil injection on shortage due to increased demand.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.

Available Products

    • Flumazenil injection, Baxter, 0.1 mg/mL, 10 mL vial, 10 count, NDC 36000-0149-10
    • Flumazenil injection, Fresenius Kabi, 0.1 mg/mL, 10 mL vial, 1 count, NDC 63323-0424-10

Estimated Resupply Dates

    • Baxter has flumazenil 0.1 mg/mL 5 mL vials on intermittent back order and the company is releasing supplies as they become available.
    • Fresenius Kabi has flumazenil 0.1 mg/mL 5 mL vials on back order and the company estimates a release date of mid-October 2021.
    • Hikma has flumazenil 5 mL and 10 mL vials on back order and the company estimates release dates of mid-October 2021 for the 5 mL vials and late-November to early-December 2021 for the 10 mL vials.

Updated

Updated October 11, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 2, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.